Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»2222Научная статьяAVAILABILITY OF INNOVATIVE MEDICATIONS AND THE DECREASE OF MORTALITY RATES IN ONCOLOGY PATIENTSKhabrievR. Uinstitute@nriph.ruIsaevaA. V-BezmelnitsynaL. Y-MeshkovD. O-BersenevaE. A-CherkasovS. N-National Research Institute for Public Health15122016651814042022Copyright © 2016,2016The decrease of mortality rates of oncology patients correlates with the number of innovative medications available in the market. Analyses of public sales indicated that five years after market authorization is not sufficient for the innovative drug to achieve saturation of the market and to satisfy existing needs. Integrated approach based on population health monitoring, innovative technologies development forecast and health technology assessment would make possible to overcome barriers preventing achieving accessibility of health interventions which and access to medical care.innovative medicationsaccessibilityavailabilityhealth technology assessmentclinical guidelinesoncology diseasesmortality during one year after diagnosiscumulative risk of dyingинновационные лекарственные препаратыдоступностьоценка технологий здравоохраненияклинико-экономический анализклинические рекомендациионкологические заболеваниясмертность в первый год после постановки диагнозакумулятивный риск умереть[World Health Organization (WHO). Investment for health: a discussion of the role of economic and social determinants. Copenhagen, Denmark: WHO Regional Office for Europe, 2002.][WHO. HIA Glossary of Terms. 2012. [cited July 2012]; http://www.who.int/hia/about/en/][Lisac M, Reimers L, Henke KD, et al. Access and choice-competition under the roof of solidarity in German health care: an analysis of health policy reforms since 2004. Health Econ Policy Law 2010; 5:3152.][Gulliford M, Figueroa-Munoz J, Morgan M, et al. What does ‘access to health care’ mean? J Health Serv Res Policy 2002;7:186-8.][Ayé R, Wyss K, Abdualimova H, et al. Illness costs to households are a key barrier to access diagnostic and treatment services for tuberculosis in Tajikistan. BMC Res Notes 2010;3:340.][McIntyre D, Thiede M, Birch S. Access as a policy-relevant concept in low- and middle-income countries. Health Econ Policy Law 2009;4:179-93.][European Journal of Cancer, 2013: 49. Заболеваемость и смертность от рака в Европе, оценка 40 стран в 2012 г. URL: http://eco.iarc.fr.][Отчет Biggest launches, 2014. Biggest Launches 2014 Copyright © 2014 EP Vantage and Evaluate Ltd. C9][Состояние онкологической помощи населения России в 2015 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России, 2015. - илл. - 236 с. ISBN 978-5-85502-210-0][Lichtenberg FR. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009. Econ Hum Biol. 2014;13:107-27.][Lichtenberg FR. The impact of therapeutic procedure innovation on hospital patient longevity: evidence from Western Australia, 20002007. Social Sci Med. 2013;77:50-9.][Lichtenberg FR, Pettersson B. The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 19972010: evidence from longitudinal, disease-level data. Econo Innov New Technol. 2013;23(3):239-73.][Lichtenberg FR, Tatar M, C alis^kan Z. The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010. Health Policy. 2014;117(3):361-73.][Lichtenberg FR. The impact of pharmaceutical innovation on disability days and the use of medical services in the United States, 1997-2010. J Human Capital. 2014;8(4).][The Impact of Pharmaceutical Innovation on Premature][Frank R. Lichtenberg. Mortality, Cancer Mortality, and Hospitalization in Slovenia,1997-2010 Applied Health Economics and Health Policy ISSN 1175-5652 Appl Health Econ Health Policy DOI 10.1007/s40258-014-0144-3][Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва 2017, УДК 616-006.04:312.6(470) «2015», ББК 55.6 З-68][Петрова Г.В., Грецова О.П., Каприн А.Д., Старинский В.В. Методические рекомендации «Характеристика и методы расчета медико-статистических показателей, применяемых в онкологии», Москва 2014, УДК 616-006.04:312.6 (470) «2014» ББК 55,6][Polina Putrik, Sofia Ramiro, Tore K Kvien, Tuulikki Sokka, e.a. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206. doi:10.1136/annrheumdis-2012-202603][Бубнова М.Г, Бутурина Е.К., Выгодин В.А., Колтунов И.Е. и др. Основы доказательной медицины. Учебное пособие. Москва 2010. УДК 616 (075.8)][Хабриев Р.У., Куликов А.Ю., Аринина Е.Е. Методологические основы фармакоэкономического анализа. Москва, Медицина, 2011.-128 с. ISBN 978-5-225-10014-8.][Brian Godman, Rickard E Malmstrom, Eduardo Diogene, Andy Gray, e.a. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev. Clin. Pharmacol. 8(1), 77-94 (2015)]